Physician profile
George Moran
NPI 1639673635
$1,150.95
in general payments reported to CMS, 2019-2025
14 companies · $107 in 2025
The $107 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $260 · 2023: $318 · 2024: $466 · 2025: $107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $891.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $890.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $263.65 | 2022-2024 | Trelegy Ellipta |
| Ucb, INC. | $170.95 | 2024 | Nayzilam, Briviact |
| Inari Medical, INC. | $168.50 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Bayer Healthcare Pharmaceuticals INC. | $149.95 | 2024 | |
| Lilly USA, LLC | $115.69 | 2022 | |
| Inspire Medical Systems, INC. | $86.35 | 2025 | Inspire |
| Novartis Pharmaceuticals Corporation | $50.61 | 2023-2024 | |
| Solventum Corporation | $30.08 | 2024 | Activ.A.C. |
| Grifols USA, LLC | $24.24 | 2024 | Prolastin-C Liquid |
| Biohaven Pharmaceutical Holding Company LTD. | $20.63 | 2022 | |
| Sanofi-Aventis U.S. LLC | $20.23 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $17.80 | 2024 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.20 | 2023 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $16.07 | 2024 | Tezspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Moran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.